| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/18/2000 | US6015573 Treatment of resistant herpes virus with nucleoside phosphate esters |
| 01/18/2000 | US6015572 Glial cells with neurotropic factors for nerve damage |
| 01/18/2000 | US6015569 Polycyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof |
| 01/18/2000 | US6015568 Anhydrous stable retinol based cosmetic or pharmaceutical composition |
| 01/18/2000 | US6015558 Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-α function |
| 01/18/2000 | US6015556 Cytotoxic drug therapy |
| 01/18/2000 | US6015551 Copolymers of carboxylic acids and multiply olefinically unsaturated carboxylic acid derivatives and their use as thickeners and dispergents |
| 01/18/2000 | US6015547 Zinc ion with anions for solutions |
| 01/18/2000 | US6015543 Diagnosis of tumors |
| 01/18/2000 | CA2184433C Retinoid formulations in porous microspheres for reduced irritation and enhanced stability |
| 01/18/2000 | CA2172472C Pyrido[3,2-e]pyrazinones with anti-asthmatic action and processes for their manufacture |
| 01/18/2000 | CA2168764C Novel quinolone carboxylic acid derivatives |
| 01/18/2000 | CA2147089C Cosmetic and/or dermatological composition containing a glycerol tri(alpha-hydroxyacylate) as the only glycerol precursor |
| 01/18/2000 | CA2142277C Anti-cancer therapeutic compositions for prophylaxis or for treatment of cancer |
| 01/18/2000 | CA2136818C Sulfur-containing phosphonate compounds for treating abnormal calcium and phosphate metabolism |
| 01/18/2000 | CA2118174C Galanthamine derivatives, a process for their preparation and their use as medicaments |
| 01/18/2000 | CA2113871C A strain of streptomyces lavendofoliae dkrs and a method for producing aclacinomycins a,b,y and aglycones using the same |
| 01/18/2000 | CA2106695C Hyaluronic acid and forms to prevent arterial restenosis |
| 01/18/2000 | CA2035314C Triazole antifungal agents |
| 01/18/2000 | CA2013474C Cyclophosphamide - alanine lyophilizates |
| 01/18/2000 | CA2010588C Substituted pyrimidine derivatives, their uses and a process for the preparation thereof |
| 01/18/2000 | CA2006587C Membrane proteins and peptides of haemophilus influenzae type b |
| 01/18/2000 | CA2003837C Fused heterocyclic derivatives of 1,2,3,4-tetrahydroacridine, a process for their preparation and their use as medicaments |
| 01/18/2000 | CA2001124C Treatment of hypertension |
| 01/18/2000 | CA2001123C Treatment of osteoporosis |
| 01/18/2000 | CA2000985C 1,4-diazepine derivative and its pharmaceutical use |
| 01/17/2000 | CA2243619A1 Chitosan- and xanthan-based polyionic hydrogels for the stabilization and controlled release of vitamins |
| 01/15/2000 | CA2239931A1 Pharmaceutical tablet comprising norfloxacin |
| 01/14/2000 | WO2000003736A1 Prostaglandin product |
| 01/13/2000 | WO2000001851A1 Antisense oligonucleotides targeted to il-15 |
| 01/13/2000 | WO2000001840A1 Fermentation process to produce clavulanic acid at a low concentration of free amino acids |
| 01/13/2000 | WO2000001811A1 Kv6.2, A VOLTAGE-GATED POTASSIUM CHANNEL SUBUNIT |
| 01/13/2000 | WO2000001805A1 Cells and animals deficient in protein kinase c epsilon |
| 01/13/2000 | WO2000001733A1 Amides of hyaluronic acid and the derivatives thereof and a process for their preparation |
| 01/13/2000 | WO2000001716A2 Vasculoprotector |
| 01/13/2000 | WO2000001714A1 Efflux pump inhibitors |
| 01/13/2000 | WO2000001704A2 Benzimidazoles, production thereof and use thereof as medicaments |
| 01/13/2000 | WO2000001703A1 Process for the preparation of 3-cephem compounds |
| 01/13/2000 | WO2000001702A1 Inhibitors of prenyl-protein transferase |
| 01/13/2000 | WO2000001701A1 Inhibitors of prenyl-protein transferase |
| 01/13/2000 | WO2000001699A1 Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer |
| 01/13/2000 | WO2000001698A1 Porphyrin derivatives and their use in photodynamic therapy and mri diagnosis |
| 01/13/2000 | WO2000001696A1 3-ALKYLPYRROLO[3,2-c]QUINOLINE DERIVATIVES |
| 01/13/2000 | WO2000001695A1 New benzoxazoles with pde-inhibiting activity |
| 01/13/2000 | WO2000001694A1 Paroxetine methanesulfonate |
| 01/13/2000 | WO2000001692A1 Salts of paroxetine |
| 01/13/2000 | WO2000001690A1 Cinnamic acid derivatives as cell adhesion molecules |
| 01/13/2000 | WO2000001689A1 Process for producing (8- chloro-3,10- dibromo-6,11- dihydro- 5h-benzo [5,6]cyclohepta [1,2-b]pyridin-11-yl)- 1-piperidine |
| 01/13/2000 | WO2000001687A1 Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| 01/13/2000 | WO2000001680A1 New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use |
| 01/13/2000 | WO2000001677A1 Piperazine derivatives inhibiting human immunodeficiency virus replication |
| 01/13/2000 | WO2000001676A1 Potassium channel blocking agents |
| 01/13/2000 | WO2000001671A2 Antihistaminic piperidine derivatives and intermediates for the preparation thereof |
| 01/13/2000 | WO2000001670A1 Substituted nitrogen and sulfur alicyclic compounds, including methods for synthesis thereof |
| 01/13/2000 | WO2000001668A2 Naaladase inhibitors useful as pharmaceutical compounds and compositions |
| 01/13/2000 | WO2000001667A1 SUBSTITUTED β-DIKETONES AND THEIR USE |
| 01/13/2000 | WO2000001666A1 C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES |
| 01/13/2000 | WO2000001662A1 Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and alkanoyl l-carnitines |
| 01/13/2000 | WO2000001650A1 Method of vitamin production |
| 01/13/2000 | WO2000001417A1 Delivery system |
| 01/13/2000 | WO2000001414A1 Use of texaphyrins in macrophage-mediated disease |
| 01/13/2000 | WO2000001411A1 Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties |
| 01/13/2000 | WO2000001399A1 Companion animal therapeutic treat |
| 01/13/2000 | WO2000001397A1 Water-soluble native dry plant extract, especially ginkgo biloba extract with a high terpenoid and flavone glycoside content |
| 01/13/2000 | WO2000001396A1 Pharmaceutical composition for treating sexual dysfunction |
| 01/13/2000 | WO2000001394A1 Biocompatible and biodegradable compositions containing hyaluronic acid and the derivatives thereof for the treatment of ulcers in the digestive apparatus |
| 01/13/2000 | WO2000001393A2 OLIGONUCLEOTIDE INHIBITORS OF bcl-xL |
| 01/13/2000 | WO2000001392A1 1-octadecyl-2-methyl-sn-glycero-3-phosphocholine (et180ch3) for the treatment of human carcinoma of the breast |
| 01/13/2000 | WO2000001391A1 Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof |
| 01/13/2000 | WO2000001389A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 01/13/2000 | WO2000001388A1 Remedies for diabetes |
| 01/13/2000 | WO2000001387A1 Fungal growth inhibitors |
| 01/13/2000 | WO2000001386A1 Farnesyl protein transferase inhibitors for treating arthropathies |
| 01/13/2000 | WO2000001385A1 Use of fk506 and related macrolides in the manufacture of a medicament for treatment or prevention of pain |
| 01/13/2000 | WO2000001384A1 Ketotifen preparation for percutaneous absorption |
| 01/13/2000 | WO2000001383A1 Angiogenesis inhibitors |
| 01/13/2000 | WO2000001382A1 Inhibitors of prenyl-protein transferase |
| 01/13/2000 | WO2000001381A1 Substituted oxygen alicyclic compounds, including methods for synthesis thereof |
| 01/13/2000 | WO2000001380A1 cyclo-oxygenase inhibitor |
| 01/13/2000 | WO2000001379A1 (-)-pseudoephedrine as a sympathomimetic drug |
| 01/13/2000 | WO2000001378A1 Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection |
| 01/13/2000 | WO2000001377A2 Nalmefene in combination with opioid analgesics |
| 01/13/2000 | WO2000001376A2 Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
| 01/13/2000 | WO2000001375A2 Calcium channel blockers |
| 01/13/2000 | WO2000001374A1 Therapeutic system with addition of nacreous pigments |
| 01/13/2000 | WO2000001371A1 Thixotropic formulations for filling capsules |
| 01/13/2000 | WO2000001369A1 Sustained release pharmaceutical preparation |
| 01/13/2000 | WO2000001368A1 Anti-inflammatory pharmaceutical formulations |
| 01/13/2000 | WO2000001366A1 A method of administering liposomal encapsulated taxane |
| 01/13/2000 | WO2000001365A1 Prolonged release ophthalmic compositions containing a fluoroquinolone |
| 01/13/2000 | WO2000001364A1 Stable pharmaceutical compositions of thieno [3,2-c] pyridine derivatives |
| 01/13/2000 | WO2000001362A1 Preparations for protecting infants' skin against diaper dermatitis |
| 01/13/2000 | WO2000001349A2 Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same |
| 01/13/2000 | WO2000001347A2 Formulations for controlling human lice |
| 01/13/2000 | WO2000001238A1 Methods for eradication of nanobacteria |
| 01/13/2000 | WO1999061417A3 Method for making hydroxy-25-ene-vitamin d compounds |
| 01/13/2000 | WO1999059628A3 Combination therapy for the treatment of tumors |
| 01/13/2000 | WO1999058540A3 1-galactose derivatives |
| 01/13/2000 | WO1999058534A3 Epothilone derivatives, a method for the production thereof, and their use |
| 01/13/2000 | WO1999058118A3 METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES |